NSE - Delayed Quote • INR Piramal Pharma Limited (PPLPHARMA.NS) Follow Compare 221.25 -15.90 (-6.70%) At close: January 10 at 3:30:00 PM GMT+5:30 All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations 3 Indian Stocks With Estimated Undervaluation In September 2024 Over the last 7 days, the Indian market has remained flat, yet it has surged by 44% over the past year with earnings forecasted to grow by 17% annually. In this context, identifying undervalued stocks can provide significant opportunities for investors looking to capitalize on potential growth and value in a thriving market. 3 Indian Exchange Stocks Estimated To Be Undervalued In July 2024 The Indian stock market has shown robust growth, rising by 2.3% in the last week and an impressive 45% over the past year, with earnings expected to grow by 16% annually. In this thriving market environment, identifying stocks that are potentially undervalued could offer investors a strategic advantage. Jindal Steel & Power And Two More Indian Exchange Stocks Considered Below Estimated Intrinsic Values The Indian stock market has experienced a notable fluctuation, declining by 1.3% over the past week, yet showing a robust increase of 43% over the past year with earnings expected to grow by 16% annually. In this context, identifying stocks like Jindal Steel & Power that are considered undervalued relative to their intrinsic values could be particularly compelling for investors looking for potential growth opportunities in a generally bullish market. Exploring Undervalued Stocks On The Indian Exchange With Discounts Ranging From 30.8% To 39.7% The Indian stock market has experienced a notable fluctuation recently, declining by 2.0% over the last week but rising by 43% over the past year with earnings expected to grow by 16% annually. In this context, identifying undervalued stocks that offer significant discounts can be particularly compelling for investors looking for potential opportunities in a growing market. Kiniksa Pharmaceuticals International And Two More Firms Possibly Priced Below Market Value Estimates As global markets exhibit mixed reactions with a notable pivot towards value and small-cap stocks, investors are keenly observing shifts in market dynamics. Amid these changing tides, identifying potentially undervalued stocks could offer intriguing opportunities for those looking to diversify their portfolios in line with current economic conditions. Performance Overview Trailing total returns as of 1/10/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX Return PPLPHARMA.NS S&P BSE SENSEX YTD -16.60% -1.11% 1-Year +54.62% +8.39% 3-Year +13.28% +29.52%